Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside
1. 442201-24-3
2. Gsk-189075
3. Gsk-189075a
4. Gsk189075a
5. Remogliflozin Etabonate [inn]
6. Tr0qt6qsul
7. Ethyl (((2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazol-3-yl)oxy)tetrahydro-2h-pyran-2-yl)methyl) Carbonate
8. Ethyl [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl Carbonate
9. 5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside
10. Unii-tr0qt6qsul
11. Kgt-1681
12. Remogliflozin Etabonate [usan]
13. Beta-d-glucopyranoside, 5-methyl-4-((4-(1-methylethoxy)phenyl)methyl)-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl Carbonate)
14. Beta-d-glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl Carbonate)
15. S0993
16. Schembl721678
17. Chembl2028665
18. Dtxsid50963191
19. Chebi:177541
20. Gsk 189075a
21. Zinc3979756
22. Remogliflozin Etabonate (usan/inn)
23. Bdbm50559516
24. Gsk189075
25. Bhv-091009
26. Db12935
27. Remogliflozin Etabonate (gsk189075)
28. Remogliflozin Etabonate [who-dd]
29. Br162756
30. Hy-14945
31. Cs-0003650
32. D10055
33. Q7312052
34. 3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)-methyl]-1-isopropyl-5-methylpyrazole
35. 3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole
36. 4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazole-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside
37. 5-methyl-1-(propan-2-yl)-4-((4-((propan-2-yl)oxy)phenyl)methyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-.beta.-d-glucopyranoside
38. 5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o- (ethoxycarbonyl)-.beta.-d-glucopyranoside
| Molecular Weight | 522.6 g/mol |
|---|---|
| Molecular Formula | C26H38N2O9 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 12 |
| Exact Mass | 522.25773079 g/mol |
| Monoisotopic Mass | 522.25773079 g/mol |
| Topological Polar Surface Area | 142 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 704 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Remogliflozin Etabonate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remogliflozin Etabonate, including repackagers and relabelers. The FDA regulates Remogliflozin Etabonate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remogliflozin Etabonate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Remogliflozin Etabonate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Remogliflozin Etabonate supplier is an individual or a company that provides Remogliflozin Etabonate active pharmaceutical ingredient (API) or Remogliflozin Etabonate finished formulations upon request. The Remogliflozin Etabonate suppliers may include Remogliflozin Etabonate API manufacturers, exporters, distributors and traders.
click here to find a list of Remogliflozin Etabonate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Remogliflozin Etabonate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Remogliflozin Etabonate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Remogliflozin Etabonate GMP manufacturer or Remogliflozin Etabonate GMP API supplier for your needs.
A Remogliflozin Etabonate CoA (Certificate of Analysis) is a formal document that attests to Remogliflozin Etabonate's compliance with Remogliflozin Etabonate specifications and serves as a tool for batch-level quality control.
Remogliflozin Etabonate CoA mostly includes findings from lab analyses of a specific batch. For each Remogliflozin Etabonate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Remogliflozin Etabonate may be tested according to a variety of international standards, such as European Pharmacopoeia (Remogliflozin Etabonate EP), Remogliflozin Etabonate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Remogliflozin Etabonate USP).
LOOKING FOR A SUPPLIER?
